Clinical Trials Browser

Phase 2 × Carcinoma, Hepatocellular × Sunitinib × Clear all

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT00787787 2017-06-01

Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer

Phase 2 Terminated

41 enrolled 9 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT00524316 2017-05-09

Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Phase 2 Terminated

16 enrolled 11 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00361309 2014-03-18

SU011248 in Advanced Hepatocellular Carcinoma

Phase 2 Completed

34 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01215565 2014-03-13

Fibrolam

Phase 2 Terminated

4 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Adenocarcinoma, Carcinoma, Digestive System Neoplasms, Fibrosis, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pathologic Processes

NCT00514228 2012-06-26

Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

45 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms